Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
17.37
-0.71 (-3.93%)
Mar 31, 2025, 2:24 PM EDT - Market open
Instil Bio Employees
Instil Bio had 14 employees as of December 31, 2024. The number of employees decreased by 35 or -71.43% compared to the previous year.
Employees
14
Change (1Y)
-35
Growth (1Y)
-71.43%
Revenue / Employee
n/a
Profits / Employee
-$5,295,357
Market Cap
113.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | -35 | -71.43% |
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TIL News
- 27 days ago - Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - GlobeNewsWire
- 2 months ago - Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
- 4 months ago - Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity - Seeking Alpha
- 7 months ago - Crude Oil Surges Over 1%; Instil Bio Shares Plunge - Benzinga
- 7 months ago - Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - GlobeNewsWire
- 7 months ago - Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements - Seeking Alpha
- 8 months ago - Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire